PHARMACOKINETICS AND PHARMACODYNAMICS OF TUCARESOL, AN ANTISICKLING AGENT, IN HEALTHY-VOLUNTEERS

被引:27
|
作者
ROLAN, PE [1 ]
MERCER, AJ [1 ]
WOOTTON, R [1 ]
POSNER, J [1 ]
机构
[1] WELLCOME RES LABS,DEPT CLIN PHARMACOL,BECKENHAM BR3 3BS,KENT,ENGLAND
关键词
TUCARESOL; ANTI-SICKLING AGENT; SICKLE CELL DISEASE; PHARMACOKINETICS; PHARMACODYNAMICS;
D O I
10.1111/j.1365-2125.1995.tb04465.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Tucaresol is an orally administered antisickling agent which increases the oxygen affinity of haemoglobin. 2 The pharmacokinetics, effects on moderate graded exercise and psychometric performance of tucaresol were examined in a double-blind, placebo-controlled, parallel groups study in 12 healthy men. 3 Three doses of tucaresol were given at 48 h intervals intended to modify 15, 25 and 32.5% of a subject's haemoglobin to a high affinity form (%MOD). 4 Mean peak %MOD was 34%. Mean C-max values in plasma and erythrocytes were 81.4 and 1459 mu g ml(-1), respectively. 5 Heart rate, compared with baseline, increased in the tucaresol group with the greatest changes at the highest %MOD and workload. There were no differences between groups in psychometric test performance. 6 Three volunteers on active drug developed fever, rash and tender cervical lymphadenopathy with onset 7-10 days from the start of dosing, suggesting an immune mechanism. 7 The acute increase in oxygen affinity with tucaresol is physiologically well-tolerated, but the utility of tucaresol in the management of sickle cell disease will depend on the identification of a dosing regimen with a lower incidence of drug allergy.
引用
收藏
页码:375 / 380
页数:6
相关论文
共 50 条
  • [1] PHARMACOKINETICS AND PHARMACODYNAMICS OF NIFEDIPINE IN HEALTHY-VOLUNTEERS
    KLEINBLOESEM, CH
    VANBRUMMELEN, P
    VANDELINDE, JA
    BREIMER, DD
    [J]. PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1983, 5 (04) : 191 - 191
  • [2] PHARMACOKINETICS AND PHARMACODYNAMICS OF GLIPIZIDE IN HEALTHY-VOLUNTEERS
    PENTIKAINEN, PJ
    NEUVONEN, PJ
    PENTTILA, A
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1983, 21 (02) : 98 - 107
  • [3] PRELIMINARY STUDIES OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PROCHLORPERAZINE IN HEALTHY-VOLUNTEERS
    TAYLOR, WB
    BATEMAN, DN
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (02) : 137 - 142
  • [4] THE INFLUENCE OF ORLISTAT ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF GLYBURIDE IN HEALTHY-VOLUNTEERS
    ZHI, J
    MELIA, AT
    KOSSTWARDY, SG
    MIN, B
    GUERCIOLINI, R
    FREUNDLICH, NL
    MILLA, G
    PATEL, IH
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (05): : 521 - 525
  • [5] INFLUENCE OF MELOXICAM ON FUROSEMIDE PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY-VOLUNTEERS
    MULLER, FO
    SCHALL, R
    DEVAAL, AC
    GROENEWOUD, G
    HUNDT, HKL
    MIDDLE, MV
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 48 (3-4) : 247 - 251
  • [6] EFFECT OF MORICIZINE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN IN HEALTHY-VOLUNTEERS
    BENEDEK, IH
    KING, SYP
    POWELL, RJ
    AGRA, AM
    SCHARY, WL
    PIENIASZEK, HJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (06): : 558 - 563
  • [7] INFLUENCE OF NICARDIPINE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PROPRANOLOL IN HEALTHY-VOLUNTEERS
    SCHOORS, DF
    VERCRUYSSE, I
    MUSCH, G
    MASSART, DL
    DUPONT, AG
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (05) : 497 - 501
  • [8] COMPARISON OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TORASEMIDE AND FUROSEMIDE IN HEALTHY-VOLUNTEERS
    LESNE, M
    [J]. ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1988, 38-1 (1A): : 160 - 163
  • [9] PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NOVEL ALDOSTERONE ANTAGONIST, MESPIRENONE, IN HEALTHY-VOLUNTEERS
    HILDEBRAND, M
    SEIFERT, W
    [J]. ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1986, 59 : 68 - 68
  • [10] RELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS OF EPTASTIGMINE IN YOUNG HEALTHY-VOLUNTEERS
    IMBIMBO, BP
    LICINI, M
    SCHETTINO, M
    MOSCA, A
    ONELLI, E
    ZECCA, L
    GIUSTINA, A
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (03): : 285 - 290